Objective: To compare methylprednisolone concentrations in the perilymph of the human ear and in plasma after intratympanic (IT) or intravenous (IV) administration. Methods: Methylprednisolone concentrations in the perilymph of patients during cochlear implantation were compared after 3 dosing strategies of methylprednisolone solution for injection (40 mg/ml): 1) IT administration of up to 40 mg was injected into the middle ear through the external auditory canal via a 27-gauge needle passed through a small anterosuperior myringotomy; 2) IV administration of 1 mg/kg was given as a single injection over 30 seconds; 3) IV administration of 10 mg/kg was infused over 30 minutes. Perilymph (single sample, È20 KL) was sampled using a needle passed through the round window membrane, from 0.5 to 3 hours after dosing. In most patients, simultaneous blood sampling was performed. Methylprednisolone concentrations were measured by highperformance liquid chromatography with a limit of quantification of 0.001 mg/L.
Systemic administration of corticosteroids has been the preferred method of treatment of a number of inner ear conditions including autoimmune inner ear disease, acute postmeningitic labyrinthitis, idiopathic sudden sensorineural hearing loss, and Cogan's syndrome. More recently, intratympanic (IT) delivery has become an accepted approach to treatment of some of these conditions. The main drugs that have been administered in humans via the IT route have been corticosteroids (1Y8) and the aminoglycosides (9, 10) , but this list could expand as more is understood. IT administration has the advantage of reducing systemic drug concentrations and side effects and the potential advantage of delivering higher doses to the inner ear when compared with the more traditional oral or intravenous (IV) routes. In addition to therapeutic use for specific diseases, it is possible that corticosteroids might be used to assist in the preservation of residual hearing during surgical procedures, such as cochlear implants.
Corticosteroids influence target tissues after interacting with intracellular glucocorticoid receptors (11) . This leads to altered expression of specific target genes to produce metabolic and anti-inflammatory effects. It is not currently known exactly how corticosteroids exert their effects in the inner ear, but corticosteroid receptors have been found in the cochleas of both rats and humans (12, 13) . Shirwany et al. (14) showed that transtympanic injection of dexamethasone resulted in a 29% increase in cochlear blood flow. Fukushima et al. (15) found increased expression of aquaporin 1 after dexamethasone administration. This membrane protein increases the ability of water to pass through a membrane.
Higher concentrations of corticosteroids have been demonstrated in perilymph after IT treatment versus oral, IV, or peritoneal treatment in animal models (16Y18). To date, no study has been published looking at corticosteroid perilymph concentrations using a human model. This is not surprising because it is difficult and invasive to get access to the site. A number of anatomical differences make it difficult to compare the results between species. Volumes of perilymph differ significantly (e.g., 160 HL in humans [19] versus 4.5 HL in guinea pigs [20] ). The round window membrane is also thicker in humans than other species (70 Hm versus 20Y40 Hm in cats, and 10Y14 Hm in rodents) (21) . In guinea pigs, there is significant communication between the perilymphatic and subarachnoid spaces via a patent cochlear aqueduct (22) . This is likely to dilute any measured concentration of a substance.
Cochlear implantation offers a unique opportunity to sample perilymph. Before opening the scala tympani, it is possible to sample a small amount of perilymph without significantly risking damage to the inner ear over and above that of the procedure itself. We chose to study methylprednisolone because Parnes et al. (16) demonstrated in their animal model that methylprednisolone achieved the highest concentration for the longest duration in both perilymph and endolymph compared with dexamethasone and hydrocortisone.
The aim of the study was to compare methylprednisolone concentrations in the perilymph of the human ear after IT or IV administration before cochlear implantation, and to measure concentrations in plasma simultaneously. A secondary aim was to attempt to build a pharmacokinetic profile for methylprednisolone in perilymph after IT administration based on single samples from subjects dosed at different time points before sampling.
MATERIALS AND METHODS

Patients
Any patient who was to receive a cochlear implant and gave informed consent was eligible for the study. The study was approved by the Upper South A Ethics Committee of the Canterbury District Health Board.
Dosing
Methylprednisolone solution for injection (40 mg/ml) was given either by direct IT injection or by IV injection. The IT dose was a maximum of 1 ml (i.e., 40 mg) given through a 27-gauge needle via anterosuperior myringotomy. The dose of 40 mg, in 1 ml, was chosen because this was the standard ampoule size, and also approximated the volume of the middle ear. The IV dose was 1 mg/kg given as a single injection, or 10 mg/kg infused for 30 minutes. The 1-mg/kg IV dose was chosen because this is a standard dose used by the surgeon (P.B.) during this procedure, and is also similar to that given IT. The higher IV dose was chosen to accord with standard high-dose methylprednisolone therapy used for other conditions. The timing of the dose before the predicted time of perilymph sampling was varied within the practical constraints of the operative setting, so that it might be possible to build up a concentration versus time curve. In practice, this meant that dosing was generally between 0.5 and 2 hours before sampling. The exact time of administration was noted. Ideally, the mode of administration (IT versus IV low dose versus IV high dose) should have been randomized, but this was not possible because of a change in study design while in progress (see Sampling).
Sampling
Perilymph (È20 KL) was sampled through a 26-gauge microsyringe needle passed through the round window when operatively exposed. The exact time of sampling was noted. In all but the first seven patients, a venous blood sample was also taken, as close as possible in time to the perilymph sample. Samples were not taken for the first seven subjects because we had initially planned to examine the pharmacokinetics of methylprednisolone in the perilymph only. However, because variation in the perilymph concentrations was so large, it was decided to change the study to a comparison between IT and IV dosing. Abnormalities in the region of the round window (e.g., adhesions, false membranes) were also looked for.
Assay
Methylprednisolone concentrations in plasma and perilymph were analyzed by high-performance liquid chromatography using a modification of a previously described method (11) . For the sample preparation, 80 KL of acetonitrile was added to 20 KL of plasma or perilymph to precipitate the proteins. The mixture was vortexed for 30 seconds and centrifuged at 15,000 Â g for 10 minutes. After centrifugation, the clear supernatant (50 KL) was transferred to a clean tube and evaporated to dryness. Residues were dissolved in 50 KL of water, and 10-KL aliquots were injected into the high-performance liquid chromatography system. A Luna C 8 (2) 3 Km, 150 Â 3.0Ymm internal diameter column (Phenomenex, Torrance, CA, USA) maintained at 60 -C was used for separation. The mobile phase was a mixture of 0.01 mol/L phosphate buffer, pH 3.5, and acetonitrile (65:35 vol/vol) containing 0.1% triethylamine, and the flow rate was 0.3 ml/min. The methylprednisolone peak was free of interference from endogenous substances present in blank plasma and proxy perilymph (the filtrate of plasma prepared by ultrafiltration [2600 g for 30 min at 37-C] using a Diaflo ultrafiltration membrane, YMT DISCS, 30K NMWL, 14 mm [Amicon Inc., Beverly, MA, USA]). Standard curves for plasma and perilymph methylprednisolone were linear (r 2 9 0.99) over the concentration ranges 0.005 to 100 mg/L. The limit of quantification was around 0.001 mg/L. Intraday and interday coefficients of variation were less than 10% at low and high concentrations.
Data Analysis
Descriptive statistics were used to describe the concentrations in perilymph and plasma. Comparisons between perilymph and plasma concentrations after IT and IV administration were made using the two-tailed Mann-Whitney U test, with p G 0.05 as the alpha cutoff value.
RESULTS
Of 39 patients who entered the study, 6 were excluded because there was insufficient sample in 5, and in the remaining patient, the IT dose was seen to disappear immediately from the middle ear, and no concentrations were measurable in either perilymph or plasma. No abnormalities were noted in the round window niche.
Ages ranged from 2 to 79 years, median 43 years, and there were 15 male and 11 female subjects (Table 1) . Of the patients with measurable samples, 18 received the dose by the IT route, 8 by IV injection of 1 mg/kg, and 7 by IV infusion of 10 mg/kg. The median dose administered IT was around 20 mg (range, 10 to e40 mg), after IV injection, 67.5 mg (range, 26Y84 mg), and after IV infusion, 770 mg (range, 570Y860 mg).
Perilymph concentrations (Fig. 1) after IT administration ranged from 0.2 to 89.4 mg/L (n = 18; median, 6.7 mg/L), after IV injection of 1 mg/kg from below the limit of quantification (LOQ) to 0.47 (n = 8; median, 0.053), and after IV infusion of 10 mg/kg from 0.067 to 3.1 mg/L (n = 7; median, 0.2). The median perilymph concentrations after IT administration were 126-fold higher after IT compared with IV injection of 1 mg/kg ( p = 0.0003; 452-fold higher if corrected for dose) and 33-fold higher than after IV infusion of 10 mg/kg ( p = 0.0045; 1,270-fold higher if corrected for dose).
Plasma samples were obtained from 19 patients (we omitted to take a sample from the first 8 patients). Plasma concentrations (Fig. 2) after IT administration ranged from below the LOQ to 0.26 mg/L (n = 11 measurable samples; median, 0.05 mg/L), after IV injection of 1 mg/kg from 0.12 to 1.19 mg/L (n = 8; median, 0.82 mg/L), and after IV infusion of 10 mg/ kg from 1.8 to 11.2 mg/L (n = 7; median, 6.8 mg/L). Samples that were below the LOQ were accorded the value of the LOQ, which was 0.001 mg/L. Any bias from this is in favor of Bno difference[ between IT and IV administration. Median plasma concentrations were 16-fold lower after IT administration than with IV injection of 1 mg/kg ( p = 0.0006; around 5-fold lower if corrected for dose), and 136-fold lower than with IV infusion of 10 mg/kg ( p = 0.0006; around 3.5-fold lower if corrected for dose).
There were no statistical differences between concentrations in either perilymph or plasma at different times of sampling (G1 h, 1Y2 h, or 2Y3 h) after dose administration. This reflects both the large variability in the results and the small numbers in each group.
DISCUSSION
Perilymph concentrations of methylprednisolone are 425-to 1,270-fold higher after IT administration compared with IV administration, corrected for dose. Plasma concentrations are around 3.5-to 5-fold lower after IT administration compared with IV administration, corrected for dose. Together, these results suggest a gain, in terms of targeting perilymph, of 2,000-to 4,500-fold with IT administration compared with IV administration. These results support animal data that suggest that IT administration results in high local concentrations but low systemic exposure (13) . In practical terms, these results suggest that if high concentrations are considered desirable in the perilymph, then these can only be achieved by IT administration.
There was large variability in the concentrations achieved in different patients after ostensibly similar doses. There are a number of reasons for this, but the major factor was probably inaccuracy in the estimation of the dose actually received by the inner ear via the IT route. We tried to estimate the dose based on the volume of solution injected. However, there was occasionally some back spillage into the external auditory canal when the middle ear was apparently Bfull.[ Furthermore, in a few patients, there seemed to be rapid disappearance of some of the injected solution from the middle ear, possibly through drainage down the eustachian tube. How long the solution in the middle ear remained over the round window would also determine the percentage of the IT injection dose that might be assimilated into the perilymph, as would the condition of the round window itself. Although no adhesions were noted within the middle ear, an air bubble over the round window could prevent access of drug to the inner ear. For these reasons, the entire dose of 40 mg may not have been available for transfer across the round window membrane. Another factor involved in variability is the small volume of the perilymph sample. Some of the samples were so small that they were unable to be successfully measured. Variability in concentrations after IV administration was also substantial, but much less so than after IT administration. Because the dose administered is likely to be accurate, most of this variability must relate to other factors, such as the large age range of our subjects (2 Y 79 years), and the different times between dosing and sampling. Despite the many sources of variability contributing to the Bnoise,[ the difference between concentrations achieved after IT administration (the Bsignal[) was very marked, as was the reciprocal change in systemic exposure. Thus, there is no ambiguity in the conclusions.
It would have been desirable to have been able to show a predictable relationship between time of dosing and concentrations achieved. However, the variability at similar time points was even greater than the variability at different time points, so it was not possible to develop a meaningful concentration versus time profile. Therefore, we have restricted our conclusions to the large difference between concentrations achieved after IT versus IV administration. One patient (number 29) had bilateral cochlear implants, enabling perilymph sampling at two different time points after IV infusion of 10 mg/kg. His concentrations in perilymph and plasma, respectively, were 0.2 and 1.8 mg/L at 1.3 hours, and 0.006 and 0.2 mg/L at 5 hours, suggesting that the perilymph behaves pharmacokinetically as if it is close to the central (blood) compartment.
Our human cochlear implant model is similar to one used by Becvarovski et al. (23Y25) in studies of gentamicin and ciprofloxacin. Their model used patients undergoing either translabyrinthine or labyrinthectomy surgery. The emerging trend of attempted preservation of residual hearing in cochlear implantation could make use of our model more difficult in the future, because removing even small volumes of perilymph may cause a decline in residual hearing. We are currently reviewing residual hearing in this group of patients as part of a larger study looking retrospectively at hearing preservation in cochlear implant surgery.
Locally delivered corticosteroids may help in the preservation of residual hearing in cochlear implantation. Animal models using triamcinolone (26) and dexamethasone (27) have shown reductions of hearing loss after implantation trauma. Clinically, local steroid use is described by Kiefer et al. (28) , who used triamcinolone within the scala tympani in hearing preservation cochlear implant surgery.
Corticosteroids are currently used in the management of sudden sensorineural hearing loss, although the evidence base for their use is not completely clear (22Y24). IT steroid use has been advocated for patients who do not respond to initial systemic treatment or have relative contraindications to systemic steroids (13,25,27Y32) . Given the vastly higher perilymph concentrations of methylprednisolone demonstrated in our study, future studies to evaluate the efficacy of steroid use in sudden sensorineural hearing loss should involve IT administration.
CONCLUSION
IT administration of up to 40 mg of methylprednisolone results in perilymph concentrations 127-fold higher than after IV injection of 1 mg/kg, and 33-fold higher than after IV infusion of 10 mg/kg. Plasma concentrations after IT administration were 16-fold lower compared with IV injection of 1 mg/kg, and 136-fold lower compared with IV infusion of 10 mg/kg. Correcting for dose, these results suggest that IT administration compared with IV administration results in a net advantage in terms of targeting the perilymph versus the plasma of around 2,000-to 4,500-fold.
